-
06:18:22 PM

NUVL Stock News

03/16/23 6:30 AM
Nasdaq : NUVL
earnings
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline and business progress and fourth quarter and full year 2022 financial results. "2022 was a remarkable year of progress for Nuvalent. The team continued to execute through...
RHEA-AI
very positive
03/14/23 5:59 PM
Nasdaq : NUVL
conferencesclinical trial
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655. The poster will be archived on the Nuvalent...
RHEA-AI
neutral
10/28/22 12:01 AM
Nasdaq : NUVL
clinical trial
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC
Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities, treatment-related serious adverse events, treatment- related dizziness, or adverse events leading to treatment reductions or discontinuations as of
RHEA-AI
neutral